摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(S)-2-(2-methylpiperidin-1-yl)-5-(trifluoromethyl)aniline | 858126-25-7

中文名称
——
中文别名
——
英文名称
(S)-2-(2-methylpiperidin-1-yl)-5-(trifluoromethyl)aniline
英文别名
(S)-2-(2-methyl-1-piperidinyl)-5-(trifluoromethyl)aniline;2-[(2S)-2-methylpiperidin-1-yl]-5-(trifluoromethyl)aniline
(S)-2-(2-methylpiperidin-1-yl)-5-(trifluoromethyl)aniline化学式
CAS
858126-25-7
化学式
C13H17F3N2
mdl
MFCD09047962
分子量
258.287
InChiKey
DARADDOCGJKKFJ-VIFPVBQESA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    3.5
  • 重原子数:
    18
  • 可旋转键数:
    1
  • 环数:
    2.0
  • sp3杂化的碳原子比例:
    0.54
  • 拓扑面积:
    29.3
  • 氢给体数:
    1
  • 氢受体数:
    5

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

点击查看最新优质反应信息

文献信息

  • Method for controlling sr protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control sr protein activity
    申请人:Hagiwara Masatoshi
    公开号:US20070135367A1
    公开(公告)日:2007-06-14
    The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
    本发明提供了:(1)通过减少或抑制SR蛋白活性作用的抗病毒剂,更具体地,(i)通过增强SR蛋白的去磷酸化作用的抗病毒剂,和(ii)通过抑制磷酸化SR蛋白的蛋白质的抗病毒剂;(2)通过抑制SR蛋白表达的抗病毒剂,和(3)通过激活拮抗SR蛋白的蛋白质的抗病毒剂。本发明还提供了抑制磷酸化SR蛋白的SRPKs的化合物。这些化合物抑制SR蛋白的活性并具有抗病毒活性。各种新病毒,包括SARS,已经出现,因此本发明提供了适用于新病毒的持久的广谱抗病毒剂。
  • METHODS FOR CONTROLLING SR PROTEIN PHOSPHORYLATION, AND ANTIVIRAL AGENTS WHOSE ACTIVE INGREDIENTS COMPRISE AGENTS THAT CONTROL SR PROTEIN ACTIVITY
    申请人:Hagiwara Masatoshi
    公开号:US20100016359A1
    公开(公告)日:2010-01-21
    The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
    本发明提供:(1)抗病毒剂,通过减少或抑制SR蛋白的活性发挥作用,更具体地,(i)通过增强SR蛋白的去磷酸化作用发挥作用的抗病毒剂,以及(ii)通过抑制磷酸化SR蛋白的蛋白质发挥作用的抗病毒剂;(2)通过抑制SR蛋白的表达发挥作用的抗病毒剂,以及(3)通过激活对抗SR蛋白的蛋白质发挥作用的抗病毒剂。本发明还提供抑制磷酸化SR蛋白的SRPKs的化合物。这些化合物抑制SR蛋白的活性,并具有抗病毒活性。各种新的病毒,包括SARS,已经出现,因此本发明提供适用于新病毒的持久广谱抗病毒剂。
  • Method for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
    申请人:——
    公开号:US07569536B2
    公开(公告)日:2009-08-04
    The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
    本发明提供以下内容:(1)抗病毒剂,通过减少或抑制SR蛋白的活性来发挥作用,更具体地,(i)通过增强SR蛋白的去磷酸化作用来发挥作用的抗病毒剂,以及(ii)通过抑制SR蛋白磷酸化的蛋白质来发挥作用的抗病毒剂;(2)通过抑制SR蛋白的表达来发挥作用的抗病毒剂,以及(3)通过激活对抗SR蛋白的蛋白质来发挥作用的抗病毒剂。本发明还提供抑制磷酸化SR蛋白的SRPKs的化合物。这些化合物抑制SR蛋白的活性,并具有抗病毒活性。各种新的病毒,包括SARS,已经出现,因此本发明提供了适用于新病毒的持久的广谱抗病毒剂。
  • Methods for controlling SR protein phosphorylation, and antiviral agents whose active ingredients comprise agents that control SR protein activity
    申请人:Masatoshi Hagiwara
    公开号:US08338362B2
    公开(公告)日:2012-12-25
    The present invention provides: (1) antiviral agents that act by reducing or inhibiting the activity of SR proteins, more specifically, (i) antiviral agents that act by enhancing dephosphorylation of SR proteins, and (ii) antiviral agents that act by inhibiting proteins that phosphorylate SR proteins; (2) antiviral agents that act by inhibiting the expression of SR proteins, and (3) antiviral agents that act by activating proteins that antagonize SR proteins. The present invention also provides compounds that inhibit SRPKs, which phosphorylate SR proteins. Such compounds inhibit the activity of SR proteins and have antiviral activities. Various new viruses including SARS have emerged, and thus the present invention provides long-lasting broad-spectrum antiviral agents applicable to new viruses.
    本发明提供了以下内容:(1)抗病毒剂,通过降低或抑制SR蛋白活性来发挥作用,更具体地说,(i)通过增强SR蛋白去磷酸化的抗病毒剂,和(ii)通过抑制SR蛋白磷酸化的蛋白质的抗病毒剂;(2)通过抑制SR蛋白表达的抗病毒剂,和(3)通过激活对抗SR蛋白的蛋白质的抗病毒剂。本发明还提供了抑制SR蛋白激酶(SRPKs)的化合物,这些化合物抑制SR蛋白的活性,并具有抗病毒活性。各种新的病毒,包括SARS,已经出现,因此本发明提供了适用于新病毒的长效广谱抗病毒剂。
  • Method of regulating phosphorylation of sr protein and antiviral agents comprising sr protein activity regulator as the active ingredient
    申请人:HAGIWARA, Masatoshi
    公开号:EP2666481A2
    公开(公告)日:2013-11-27
    The present invention is related to an aniline derivative represented by the following formula (I): wherein, R1, R2, R3, R4, Q and W are defined elsewhere. A typical compound of the aniline derivatives of invention is depicted in the figure. The aniline derivatives of invention have antiviral activity
    本发明涉及一种由下式(I)表示的苯胺衍生物: 其中,R1、R2、R3、R4、Q 和 W 在别处定义。本发明苯胺衍生物的典型化合物如图所示。本发明的苯胺衍生物具有抗病毒活性
查看更多